Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM. Reckamp KL, et al. Among authors: gardner bk. J Thorac Oncol. 2008 Feb;3(2):117-24. doi: 10.1097/JTO.0b013e3181622bef. J Thorac Oncol. 2008. PMID: 18303430 Free article. Clinical Trial.
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, Milne GL, Figlin RA, Fishbein MC, Elashoff RM, Dubinett SM. Reckamp KL, et al. Among authors: gardner bk. Cancer. 2015 Sep 15;121(18):3298-306. doi: 10.1002/cncr.29480. Epub 2015 May 29. Cancer. 2015. PMID: 26033830 Free PMC article. Clinical Trial.
Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer.
Krysan K, Cui X, Gardner BK, Reckamp KL, Wang X, Hong L, Walser TC, Rodriguez NL, Pagano PC, Garon EB, Brothers JF 2nd, Elashoff D, Lee JM, Spira AE, Sharma S, Fishbein MC, Dubinett SM. Krysan K, et al. Among authors: gardner bk. Am J Transl Res. 2013 Aug 15;5(5):481-96. eCollection 2013. Am J Transl Res. 2013. PMID: 23977408 Free PMC article.
Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy.
Liclican EL, Walser TC, Hazra S, Krysan K, Park SJ, Pagano PC, Gardner BK, Larsen JE, Minna JD, Dubinett SM. Liclican EL, et al. Among authors: gardner bk. Cancer Prev Res (Phila). 2014 Aug;7(8):845-55. doi: 10.1158/1940-6207.CAPR-14-0063. Epub 2014 Jun 9. Cancer Prev Res (Phila). 2014. PMID: 24913817 Free PMC article.
The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.
Krysan K, Tran LM, Grimes BS, Fishbein GA, Seki A, Gardner BK, Walser TC, Salehi-Rad R, Yanagawa J, Lee JM, Sharma S, Aberle DR, Spira AE, Elashoff DA, Wallace WD, Fishbein MC, Dubinett SM. Krysan K, et al. Among authors: gardner bk. Cancer Res. 2019 Oct 1;79(19):5022-5033. doi: 10.1158/0008-5472.CAN-19-0153. Epub 2019 May 29. Cancer Res. 2019. PMID: 31142513 Free PMC article.
109 results